Singular GenomicsOMIC
OMIC
About: Singular Genomics Systems Inc is a life science technology company that is leveraging novel next generation sequencing and multiomics technologies to build products that empower researchers and clinicians. The product development pipeline comprises two initial integrated solutions, each designed to leverage Sequencing Engine and purpose built to address different applications. The G4 Sequencing Platform is designed to target the NGS market. The PX Integrated Solution is designed to target the single cell, spatial analysis and proteomics markets. Both integrated solutions are used in many different and diverse market segments, including basic biology, oncology, immunology, neurology, genetic diseases, infectious diseases, the human microbiome and many others.
Employees: 127
0
Funds holding %
of 6,823 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
207% more capital invested
Capital invested by funds: $6M [Q2] → $18.4M (+$12.4M) [Q3]
50% more funds holding in top 10
Funds holding in top 10: 2 [Q2] → 3 (+1) [Q3]
18.25% more ownership
Funds ownership: 28.75% [Q2] → 47.01% (+18.25%) [Q3]
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
8% less funds holding
Funds holding: 24 [Q2] → 22 (-2) [Q3]
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
Research analyst outlook
We haven’t received any recent analyst ratings for OMIC.
Financial journalist opinion
Based on 13 articles about OMIC published over the past 30 days
Neutral
Accesswire
4 hours ago
Investors With Losses Are Invited To Join The Schall Law Firm In An Inquiry Into Singular Genomics Systems, Inc. For Securities Fraud
LOS ANGELES, CA / ACCESS Newswire / January 22, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Singular Genomics Systems, Inc. ("Singular Genomics" or "the Company") (NASDAQ:OMIC) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Singular Genomics board breached its fiduciary duties to shareholders.
Neutral
Business Wire
22 hours ago
SINGULAR GENOMICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Singular Genomics Systems, Inc. - OMIC
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Singular Genomics Systems, Inc. (NasdaqCM: OMIC) to an affiliate of Deerfield Management Company, L.P. Under the terms of the proposed transaction, shareholders of Singular will receive $20.00 in cash for each share of Singular that they own. KSF is seeking to determine whether this consideration and the proce.
Neutral
Accesswire
1 day ago
Singular Genomics Systems, Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Affected Shareholders To Reach Out
LOS ANGELES, CA / ACCESS Newswire / January 21, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Singular Genomics Systems, Inc. ("Singular Genomics" or "the Company") (NASDAQ:OMIC) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Singular Genomics board breached its fiduciary duties to shareholders.
Neutral
Accesswire
2 days ago
Investors With Losses Are Invited To Join The Schall Law Firm In An Inquiry Into Singular Genomics Systems, Inc. For Securities Fraud
LOS ANGELES, CA / ACCESS Newswire / January 20, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Singular Genomics Systems, Inc. ("Singular Genomics" or "the Company") (NASDAQ:OMIC) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Singular Genomics board breached its fiduciary duties to shareholders.
Neutral
Accesswire
3 days ago
Singular Genomics Systems, Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Affected Shareholders To Reach Out
LOS ANGELES, CA / ACCESS Newswire / January 19, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Singular Genomics Systems, Inc. ("Singular Genomics" or "the Company") (NASDAQ:OMIC) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Singular Genomics board breached its fiduciary duties to shareholders.
Neutral
Accesswire
4 days ago
Investors With Losses Are Invited To Join The Schall Law Firm In An Inquiry Into Singular Genomics Systems, Inc. For Securities Fraud
LOS ANGELES, CA / ACCESS Newswire / January 18, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Singular Genomics Systems, Inc. ("Singular Genomics" or "the Company") (NASDAQ:OMIC) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Singular Genomics board breached its fiduciary duties to shareholders.
Neutral
Accesswire
4 days ago
Singular Genomics Systems, Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Affected Shareholders To Reach Out
LOS ANGELES, CA / ACCESS Newswire / January 17, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Singular Genomics Systems, Inc. ("Singular Genomics" or "the Company") (NASDAQ:OMIC) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Singular Genomics board breached its fiduciary duties to shareholders.
Neutral
Business Wire
5 days ago
OMIC Investors Have the Opportunity to Join Investigation of Singular Genomics Systems, Inc. with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)--OMIC Investors Have the Opportunity to Join Investigation of Singular Genomics Systems, Inc. with the Schall Law Firm.
Neutral
Business Wire
1 week ago
OMIC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Singular Genomics Systems, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Singular Genomics Systems, Inc. (NASDAQ: OMIC) to an affiliate of Deerfield Management Company, L.P. for $20.00 per share is fair to Singular Genomics shareholders. Halper Sadeh encourages Singular Genomics shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpers.
Neutral
Business Wire
2 weeks ago
SINGULAR GENOMICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Singular Genomics Systems, Inc. - OMIC
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Singular Genomics Systems, Inc. (NasdaqCM: OMIC) to an affiliate of Deerfield Management Company, L.P. Under the terms of the proposed transaction, shareholders of Singular will receive $20.00 in cash for each share of Singular that they own. KSF is seeking to determine whether this consideration and the proce.
Charts implemented using Lightweight Charts™